| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neurology, Vol 50, Issue 6 1746-1749, Copyright © 1998 by American Academy of Neurology
ARTICLES |
KE Crutchfield, NJ Patronas, JM Dambrosia, KP Frei, TK Banerjee, NW Barton and R Schiffmann
Developmental and Metabolic Neurology Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1260, USA.
OBJECTIVE: This study's purpose was to obtain a quantitative natural history of the cerebrovascular involvement in Fabry disease. BACKGROUND: Fabry disease is an X-linked recessive disorder due to alpha-galactosidase A deficiency. Progressive accumulation of ceramidetrihexoside within the intima and media of cerebral blood vessels causes ischemic lesions in the majority of affected patients. Determination of the natural history of the cerebral vasculopathy in Fabry disease is important to assess the effects of therapeutic intervention in this disorder. METHODS: A longitudinal MRI study of 50 patients who had a total of 129 MRI scans was performed. The burden of cerebrovascular disease was determined using direct linear measurement. RESULTS: On T2-weighted MRI scans, 32% of the patients had no lesions (mean age, 33 years), 16% had gray matter lesions only (mean age, 36 years), 26% had lesions in white matter only (mean age, 43 years), and 26% had lesions in white and gray matter (mean age, 47 years). Disease burden increased with age, but no patient younger than 26 had lesions on MRI. All patients older than 54 had cerebrovascular involvement. The distribution of MRI-detectable lesions was typical of a small-vessel disease. Only 37.5% of patients with cerebral lesions had neurologic symptoms. CONCLUSION: These findings provide a predictable outcome measure to assess the effect of molecular interventions on the cerebrovascular circulation in Fabry disease.
This article has been cited by other articles:
|
|
 |
|
  J Albrecht, P R Dellani, M J Muller, I Schermuly, M Beck, P Stoeter, A Gerhard, and A Fellgiebel Voxel based analyses of diffusion tensor imaging in Fabry disease J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 964 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Faggiano, A. Pisani, F. Milone, M. Gaccione, M. Filippella, A. Santoro, G. Vallone, F. Tortora, M. Sabbatini, L. Spinelli, et al. Endocrine Dysfunction in Patients with Fabry Disease J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4319 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gavazzi, W. Borsini, L. Guerrini, R. Della Nave, M. A. Rocca, C. Tessa, S. Buchner, G. Belli, M. Filippi, N. Villari, et al. Subcortical Damage and Cortical Functional Changes in Men and Women with Fabry Disease: A Multifaceted MR Study. Radiology, November 1, 2006; 241(2): 492 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Garzuly, L. Marodi, M. Erdos, J. Grubits, Z. Varga, E. Gelpi, B. Rohonyi, M. Mazlo, A. Molnar, and H. Budka Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the {alpha}-galactosidase A gene Brain, September 1, 2005; 128(9): 2078 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Percy and E. M. Kaye Does gender parity exist in Fabry disease? Neurology, August 23, 2005; 65(4): 508 - 509. [Full Text] [PDF]
|
|
|
|
|
|
A. Fellgiebel, M. J. Muller, M. Mazanek, K. Baron, M. Beck, and P. Stoeter White matter lesion severity in male and female patients with Fabry disease Neurology, August 23, 2005; 65(4): 600 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Moore, F. Ye, R. Schiffmann, and J. A. Butman Increased Signal Intensity in the Pulvinar on T1-Weighted Images: A Pathognomonic MR Imaging Sign of Fabry Disease AJNR Am. J. Neuroradiol., June 1, 2003; 24(6): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Takanashi, A. J. Barkovich, W. P. Dillon, E. H. Sherr, K. A. Hart, and S. Packman T1 Hyperintensity in the Pulvinar: Key Imaging Feature for Diagnosis of Fabry Disease AJNR Am. J. Neuroradiol., May 1, 2003; 24(5): 916 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Mohanraj, J P Leach, J C Broome, and D F Smith Neurological presentation of Fabry's disease in a 52 year old man J. Neurol. Neurosurg. Psychiatry, September 1, 2002; 73(3): 340 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K D MacDermot, A Holmes, and A H Miners Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males J. Med. Genet., November 1, 2001; 38(11): 750 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schiffmann, J. B. Kopp, H. A. Austin III, S. Sabnis, D. F. Moore, T. Weibel, J. E. Balow, and R. O. Brady Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial JAMA, June 6, 2001; 285(21): 2743 - 2749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Brady and R. Schiffmann Clinical Features of and Recent Advances in Therapy for Fabry Disease JAMA, December 6, 2000; 284(21): 2771 - 2775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hassan and H. S. Markus Genetics and ischaemic stroke Brain, September 1, 2000; 123(9): 1784 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tedeschi, S. Bonavita, T. K. Banerjee, A. Virta, and R. Schiffmann Diffuse central neuronal involvement in Fabry disease: A proton MRS imaging study Neurology, May 1, 1999; 52(8): 1663 - 1663. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
